Zhang Zhongtao is currently the director of general surgery, the director of surgical teaching and research section, the deputy director of Beijing Digestive Disease Center and the director of liver transplantation department of Beijing Digestive Disease Center. Engaged in general surgery for more than 20 years, specializing in the diagnosis and surgical treatment of hepatobiliary, pancreatic and gastrointestinal tumors. Working in the clinical front line all the year round, with comprehensive professional knowledge, exquisite surgical skills and rich clinical experience, he has rich experience in dealing with complex and difficult diseases. The restrictive portocaval shunt was technically innovated. Many beneficial attempts have been made in minimally invasive surgery. He has been engaged in basic and clinical research of hepatobiliary, pancreatic and gastrointestinal surgery for a long time and has profound academic attainments. In these fields, the first author has published more than 40 papers, edited or edited monograph 12, and won 9 scientific research achievement awards. Won the honorary title of "Beijing Young and Middle-aged Key Teacher". Enjoy the special government allowance of the State Council.

The basic and clinical research of portal hypertension in liver cirrhosis has always been the focus of general surgery in Beijing Friendship Hospital affiliated to Capital Medical University. Zhang Zhongtao, as the main researcher, made great technical innovation on the basis of animal experiments. After intensive perfusion with restraint ring and hepatic artery, the incidence of encephalopathy decreased from 65438 00.2% to 5.65438 0%. At the same time, the perioperative liver function protection was systematically studied, and the basic research on the pathogenesis and delaying process of liver fibrosis was carried out. The proposal and innovation of this operation is the first at home and abroad, and its technical indicators have reached the international advanced level, and its clinical effect ranks at the international leading level. Through the comprehensive and systematic study of this subject, the prevention and treatment level of portal hypertension has been improved, and it has been widely used in clinic and achieved good social benefits. He has successively won the third prize of Beijing Science and Technology Progress Award (1998), the second prize of Beijing Science and Technology Progress Award (2002) and the third prize of China Medical Science and Technology Award (2002). On the basis of animal experimental research, liver transplantation has been successfully carried out in clinic, which brings hope to patients with end-stage liver disease. The success rate and 1 year survival rate of liver transplantation cases have exceeded 80%, which is close to the international advanced level. Because China is a region with high incidence of hepatitis B, most patients with benign end-stage liver disease are hepatitis B patients, which makes liver transplantation unique in China. Comrade Zhang Zhongtao focused the clinical research of liver transplantation on long-term control of hepatitis B recurrence after liver transplantation. Their comprehensive measures to prevent the recurrence of hepatitis B after liver transplantation have achieved encouraging results in clinic. From the results, the negative rate of hepatitis B after operation was 100%, and the long-term control rate of hepatitis B was 100%.